Hair Loss Statistics in Newcastle

By Dr Aziz Elgindi, Hair Restoration Surgeon, Hair Transplant Newcastle

Newcastle has two universities. That sounds like a demographic footnote, but it actually shapes the practice in a way that’s hard to explain until you’ve worked here for a while. A significant portion of the men who come through the door at Hair Transplant Newcastle are in their early twenties. Students, or recently graduated. They noticed something changing during their first or second year and spent the next eighteen months trying to work out whether it was worth taking seriously.

That’s not a Newcastle-only story, but the concentration here is notable. When two large universities sit in a city with a population just over 300,000, the proportion of residents in the 18 to 25 bracket is unusually high compared to most UK cities. And that demographic sits right in the window where androgenetic alopecia starts becoming visible for the men who are going to be significantly affected by it.

The question most of them ask first is whether it’s actually happening, or whether they’re imagining it. They’re usually not imagining it.

Something I notice consistently about the men who come from further out

The clinic draws from a wider geography than the city itself. Men come from Gateshead, from County Durham, from Northumberland, from across Tees Valley. The North East doesn’t have a dense network of hair restoration clinics the way London does, so Newcastle functions as the regional option for a much larger population than the city boundaries suggest.

The men who travel further tend to have been waiting longer. There’s something about making a specific journey, rather than just showing up somewhere local, that seems to raise the threshold for when people decide to act. By the time someone drives in from Hexham or Durham, they’ve typically been watching the change for two or three years. Sometimes more. The loss is further progressed than it would have been if they’d come in earlier, which doesn’t mean nothing can be done, but it does mean the conversation about what’s achievable is a different one.

The early-stage conversation is easier. That’s worth knowing if you’re at the beginning of this.

The women who come in, and why the numbers don’t capture them

The NHS estimates around 8 million women in the UK have some form of hair loss. That figure is almost certainly an undercount, and not because the research is poor. Female pattern hair loss presents differently from male pattern baldness: diffuse thinning across the crown and top of the scalp, the parting gradually widening, overall density dropping in a way that’s easy to style around for a long time before it becomes difficult to conceal. Women who are very aware of it can go years before a GP or a dermatologist sees it, because it’s never quite obvious enough to prompt an appointment.

Hormonal factors are central in a way they aren’t for men. Menopause is the most significant driver in older women, the reduction in oestrogen shifting the hormonal balance toward androgens. Post-pregnancy shedding is usually temporary but can occasionally trigger longer-term changes in women who were already susceptible. Polycystic ovary syndrome raises androgen levels and is worth ruling out in younger women presenting with diffuse thinning.

We see women regularly at the Newcastle clinic. It’s not a specialist niche. The assessment and any surgical planning use different criteria from the male assessment, but the clinical process is largely the same.

What’s actually behind the loss

Androgenetic alopecia is the cause in the vast majority of cases, and the mechanism is worth understanding clearly because a lot of what circulates about hair loss misrepresents it. The hormone involved is DHT, a derivative of testosterone, which binds to receptors in follicles that are genetically sensitive to it. Those follicles miniaturise progressively over years, producing finer and shorter hair until eventually they stop producing visible hair at all.

The genetic inheritance is more complex than the maternal grandfather story people repeat. Multiple gene variants are involved, from both parental lines, and the outcomes between men with similar family histories can vary substantially. Brothers with the same grandfather and the same father’s hairline can be on opposite ends of the Norwood scale by their forties.

Telogen effluvium is the second type that comes up regularly in assessments. It’s not genetic. It’s the hair cycle responding to a systemic shock: illness, surgery, significant weight loss, thyroid dysfunction, a sustained period of high psychological stress. Shedding typically starts eight to twelve weeks after the triggering event, which is the part that causes most of the confusion. The person in the consultation is looking for what changed recently, and the actual cause was something that happened months earlier. Post-COVID telogen effluvium was something we saw in some volume through 2021 and into 2022.

The distinction between the two matters clinically. Telogen effluvium is usually temporary. Starting someone on medication designed for androgenetic alopecia when the cause is something else isn’t the right call.

On medication: what it does and what it doesn’t

Finasteride and minoxidil are the two drugs that come up in almost every consultation, and there’s a consistent misunderstanding about both of them that’s worth addressing directly. Neither drug restores hair that has already been lost. What they do is slow ongoing loss: finasteride by inhibiting the enzyme that converts testosterone to DHT, reducing the signal that’s miniaturising the follicles; minoxidil by extending the follicle’s active growth phase and improving blood flow to the scalp.

For men where loss is still actively progressing, using one or both medications alongside surgery is usually the right approach. Transplanting into an area where loss is going to continue without medical management means the result will change over time in ways that are hard to plan around.

Surgery, and what the planning actually involves

FUE is the primary method used here. Individual follicular units extracted from the donor zone at the back and sides of the scalp, where the hair is genetically resistant to DHT, and placed into the thinning areas. The ISHRS 2023 Practice Census put global hair restoration procedures at over 650,000 in a single year, with FUE accounting for the majority of those. Graft survival rates in properly performed FUE sit between 90 and 95% in the clinical literature.

FUT, the strip method, remains the better option for some patients who need a high graft count in a single session. The choice depends on specific factors in each case, not on a blanket preference.

Hairline restoration and crown restoration need genuinely different planning conversations. Frontal work tends to be high impact relative to graft count, it’s visible in every reflection and photograph. Crown work covers more surface area and carries a longer planning horizon, partly because crown loss can continue after a procedure if the underlying progression hasn’t been addressed medically. Getting the sequencing right is more important than most patients realise when they first come in.

What any of this costs depends on graft count, technique, and what’s included in the aftercare package. The right starting point is a free consultation, where a surgeon looks at what’s actually there, grades the loss accurately, assesses the donor, and gives a straight account of what’s realistic. That conversation doesn’t commit you to anything.

References